Multi-Agent Portfolio

Digest de scouts: X/opportunity scanner + top holdings 13F + news. Lo consume el consejo (Sentiment/Quant/Fundamental → Risk → PM) en el postmarket.

# MAP Sources Digest — 2026-09-08

_Generated 2026-09-08T20:16:16.267816+00:00_

## 1) Opportunity / X scanner

- Scan: `2026-09-07` · ideas=3 · rejected=10

### Ideas (passed filters)
- **IRD** — Según el discurso en X, se espera topline de OPGx-BEST1 Fase 1/2 el 9-sep-2026.
- **CLYM** — Según el discurso en X, datos de Fase 1 de CLYM116 mostraron más de 90% de supresión de APRIL y reducciones de IgA/Gd-IgA1.
- **CGEM** — El discurso en X incluye zipalertinib y un readout de Fase 3 esperado durante septiembre.

### X discourse — top rejected (still useful signal)
- **SMMT** (2.77% 1d / 28.22% 5d) — Según el discurso en X, HARMONi-2 mostró beneficio de supervivencia frente a pembrolizumab y se espera un catalizador de datos/presentación en WCLC.
  - catalysts: Beneficio OS HARMONi-2, Catalizador WCLC
  - rejected: extended_chase (dist_ma20=24.76%, day=2.77%)
  - risks: Biotech binaria, short interest y riesgo de que datos posteriores no confirmen el beneficio.
- **CADL** (-1.46% 1d / -2.22% 5d) — Según el discurso en X, datos de LuTK02 mostraron mOS de 24.5 meses y una señal clínica que podría respaldar la Fase 3.
  - catalysts: Datos LuTK02, Fase 3 en NSCLC
  - rejected: volume_ratio_below_0.8 (0.44)
  - risks: La señal debe confirmarse en Fase 3; riesgo clínico y de ejecución.
- **KOD** (-2.75% 1d / -6.26% 5d) — El discurso en X identifica datos top-line de Fase 3 de tarcocimab como catalizador inmediato en la semana biotech.
  - catalysts: Top-line Fase 3 tarcocimab
  - rejected: structure_breakdown
  - risks: Resultado clínico binario y riesgo de volatilidad alrededor del readout.
- **IREN** (7.27% 1d / 26.04% 5d) — Según el discurso en X, contratos de data centers AI y estimaciones de TCV de hasta $20–22B sostienen la tesis de infraestructura.
  - catalysts: Contratos AI/data centers, TCV estimado $20–22B
  - rejected: volume_ratio_below_0.8 (0.78)
  - risks: Alta sensibilidad a ejecución, capex y exposición parcial a minería cripto.
- **TYRA** (15.25% 1d / 14.88% 5d) — Según el discurso en X, se espera un readout de Fase 2 de TYRA-300 alrededor del 9-sep, con call de la compañía.
  - catalysts: Readout Fase 2 TYRA-300 alrededor del 9-sep
  - rejected: extended_chase (dist_ma20=10.86%, day=15.25%)
  - risks: Evento clínico binario y riesgo de dilución/financiamiento.
- **TARS** (9.1% 1d / 26.51% 5d) — Según el discurso en X, la adquisición de Alkeus agrega el programa Fase 3 oral gildeuretinol para Stargardt.
  - catalysts: Adquisición de Alkeus, Programa Fase 3 ALK-001
  - rejected: extended_chase (dist_ma20=23.66%, day=9.1%)
  - risks: Riesgo de integración y ejecución clínica/comercial del pipeline adquirido.
- **SLS** (1.17% 1d / 4.92% 5d) — El discurso en X sigue el programa GPS y la Fase 3 REGAL en AML, con datos de combinación que muestran activación de células T.
  - catalysts: Fase 3 REGAL AML, Datos de combinación con pembrolizumab
  - rejected: volume_ratio_below_0.8 (0.65)
  - risks: Biotech binaria, incertidumbre sobre eventos de supervivencia y financiamiento.
- **ZETA** (-4.07% 1d / 2.65% 5d) — Según el discurso en X, Q2 mostró revenue de $443M, crecimiento reportado de 44%, FCF de $58M y guía elevada.
  - catalysts: Q2 revenue $443M, Guía elevada, FCF $58M
  - rejected: volume_ratio_below_0.8 (0.52)
  - risks: Riesgo de ejecución y de que el crecimiento/guía ya esté reflejado en el precio.

## 2) 13F top holdings (latest filing on disk)

### Berkshire — filing 2026-08-14 · 29 names
- APPLE INC: $65.95B (22.04%)
- AMERICAN EXPRESS CO: $51.282B (17.14%)
- COCA COLA CO: $32.508B (10.86%)
- ALPHABET INC: $28.158B (9.41%)
- BANK OF AMER CORP: $27.544B (9.2%)
- CHEVRON CORPORATION: $13.986B (4.67%)
- OCCIDENTAL PETE CORP: $12.868B (4.3%)
- CHUBB LIMITED: $11.67B (3.9%)

### Pershing Square — filing 2026-05-15 · 11 names
- BROOKFIELD CORP: $2.416B (17.62%)
- AMAZON COM INC: $2.385B (17.39%)
- UBER TECHNOLOGIES INC: $2.155B (15.71%)
- MICROSOFT CORP: $2.093B (15.26%)
- RESTAURANT BRANDS INTL INC: $1.674B (12.2%)
- META PLATFORMS INC: $1.522B (11.1%)
- HOWARD HUGHES HOLDINGS INC: $1.193B (8.7%)
- SEAPORT ENTMT GROUP INC: $0.108B (0.79%)

### Scion/Burry — filing 2025-11-03 · 8 names
- PALANTIR TECHNOLOGIES INC: $0.912B (66.04%)
- NVIDIA CORPORATION: $0.187B (13.51%)
- PFIZER INC: $0.153B (11.07%)
- HALLIBURTON CO: $0.061B (4.45%)
- MOLINA HEALTHCARE INC: $0.024B (1.73%)
- LULULEMON ATHLETICA INC: $0.018B (1.29%)
- SLM CORP: $0.013B (0.96%)
- BRUKER CORP: $0.013B (0.95%)

### Appaloosa — filing 2026-08-14 · 27 names
- AMAZON COM INC: $1.192B (15.43%)
- MICRON TECHNOLOGY INC: $1.125B (14.57%)
- TAIWAN SEMICONDUCTOR MANUFAC: $0.788B (10.2%)
- ALPHABET INC: $0.654B (8.46%)
- UBER TECHNOLOGIES INC: $0.555B (7.19%)
- ISHARES INC: $0.49B (6.34%)
- META PLATFORMS INC: $0.38B (4.92%)
- VISTRA CORP: $0.351B (4.55%)

### ARK — filing 2026-08-14 · 191 names
- Tesla Inc: $1.161B (7.54%)
- Advanced Micro Devices Inc: $0.823B (5.34%)
- Space Exploration Technologies Corp: $0.765B (4.97%)
- Tempus AI Inc: $0.581B (3.77%)
- Robinhood Markets Inc: $0.525B (3.41%)
- CRISPR Therapeutics AG: $0.516B (3.35%)
- Shopify Inc: $0.475B (3.08%)
- Twist Bioscience Corp: $0.468B (3.04%)

### Tiger Global — filing 2026-08-14 · 46 names
- TAIWAN SEMICONDUCTOR MANUFAC: $2.331B (9.72%)
- AMAZON COM INC: $2.308B (9.62%)
- NVIDIA CORPORATION: $2.241B (9.34%)
- ALPHABET INC: $2.075B (8.65%)
- META PLATFORMS INC: $1.59B (6.63%)
- LAM RESEARCH CORP: $1.371B (5.72%)
- SEA LTD: $1.204B (5.02%)
- APPLIED MATLS INC: $1.18B (4.92%)

## 3) News (yfinance / map_research)

- SPY $765.96 · 5d 0.55% (H 774.03 / L 759.48)

### MSFT
- What investors 'really' need to see from Oracle earnings this week (Yahoo Finance Video, 2026-09-08)
- Google Cloud Boss Makes Bold Claim About AI Chip Business (Investor's Business Daily, 2026-09-08)
- Will Direct TPU Sales Re-Rate Google Stock? (Trefis, 2026-09-08)

### GOOGL
- What investors 'really' need to see from Oracle earnings this week (Yahoo Finance Video, 2026-09-08)
- Google Cloud Boss Makes Bold Claim About AI Chip Business (Investor's Business Daily, 2026-09-08)
- Will Direct TPU Sales Re-Rate Google Stock? (Trefis, 2026-09-08)

### AMZN
- Qualcomm and Amazon ink deal for custom data center chips (Yahoo Finance, 2026-09-08)
- What investors 'really' need to see from Oracle earnings this week (Yahoo Finance Video, 2026-09-08)
- Sector Update: Tech Stocks Rise Late Afternoon (MT Newswires, 2026-09-08)

### JPM
- Why Corporate Bonds Are Giving Treasuries a Tough Time (Barrons.com, 2026-09-08)
- Goldman Stock Gains 38.6% in a Year: Buy Now or Wait for a Pullback? (Zacks, 2026-09-08)
- Why Micron Stock Can Benefit from Fresh Memory-Chip Price Data (Barrons.com, 2026-09-08)

### LLY
- Amgen Stock Poised for Worst Day in More Than Two Decades (The Wall Street Journal, 2026-09-08)
- Why the CNS boom owes its success to breakthroughs in neurological pathologies (Pharmaceutical Technology, 2026-09-08)
- How Novartis' Double-Stacked Failures Reverberated Through Biopharma (Investor's Business Daily, 2026-09-08)

### BRK-B
- GE's CPP Deal Isn't About EPS Accretion, Says Jefferies — It's 'An Impactful Move In The Blades & Vanes War Games' (Stocktwits, 2026-09-08)
- Warren Buffett’s Portfolio Has Half Its Stock Money in Just 3 Names. Here Is What They Are. (24/7 Wall St., 2026-09-08)
- Markel Taps California's Workers' Compensation Market With Midwest (Zacks, 2026-09-08)

### XOM
- Oil Prices Are Once Again on the Brink of $100 (Oilprice.com, 2026-09-08)
- Imperial Oil Stock Rises 49% YTD: Time to Hold or Lock in Profits? (Zacks, 2026-09-08)
- ExxonMobil Has Raised Its Dividend 43 Years Running. Here's the One Year the Streak Almost Broke. (Motley Fool, 2026-09-08)

### V
- Visa Falls as UPI's Quarterly Pace Tops Its 71.7 Billion Transactions (GuruFocus.com, 2026-09-08)
- Visa Taps Onchain Lending to Finance Stablecoin Card Programs (decrypt, 2026-09-08)
- Visa Taps Onchain Credit for Stablecoin Card Settlement (Bankless, 2026-09-08)

### ZYME
- JAZZ Rises on Updated OS Results From Gastric Cancer Study (Zacks, 2026-09-01)
- Zymeworks (ZYME), What Is Behind The Renewed Attention? (Simply Wall St., 2026-08-28)
- Is Zymeworks (ZYME) Stock Fully Priced After Its 301% Run? (Simply Wall St., 2026-08-28)

### SPY
- Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14% (24/7 Wall St., 2026-09-08)
- Prediction: This ETF Will Beat the SPY Through 2027 (Not the QQQ!) (24/7 Wall St., 2026-09-08)
- Enphase Energy Rises 5% as Solid-State Transformer Modules Enter Texas Production, SolarEdge Jumps 6% (24/7 Wall St., 2026-09-08)

## Cómo usar esto (Bull / Bear / PM)

- Bull: priorizá catalysts de la sección X + news alineados a momentum USA.
- Bear: usá reasons_rejected + risks + concentración 13F como veto/overcrowding.
- PM: no copies 13F ciegamente; es contexto, no orden.